Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women

M. C. Gelato, O. H. Pescovitz, F. Cassorla, Donald (Lynn) Loriaux, G. R. Merriam

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Human GRF-(1-44)-NH2 (GRF-44) was administered iv in graded doses of 0.01-10 μg/kg to 35 normal young adult men and 38 women. GRF-44 stimulated the release of GH in a dose-dependent fashion, although the individual responses varied widely. The ED50 values for this effect were 0.4 μg/kg in men and 0.2 μg/kg in women in the midfollicular phase of the menstrual cycle. Maximal responses in men and women were not significantly different, and a dose of 1 μg/kg was sufficient to produce a maximal response. There was, likewise, no difference between responses of women tested in the midfollicular and midluteal phases of the cycle. There were no changes in PRL, LH, FSH, TSH, ACTH, β-endorphin, or cortisol at doses up to 1 μg/kg; at 10 μg/kg, PRL increased by an average of 7.6 ng/ml in the women. Side effects occurred in approximately 20% of both men and women at 1 μg/kg and in nearly all subjects given 10 μg/kg; these consisted primarily of flushing and a sense of warmth. Thus, a dose of 1 μg/kg GRF-44 is safe and effective, and would appear to be a reasonable choice for use in studying GH responses in normal subjects of other ages and in patients with disorders of GH secretion.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume59
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Young Adult
Endorphins
Adrenocorticotropic Hormone
Hydrocortisone
Menstrual Cycle

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women. / Gelato, M. C.; Pescovitz, O. H.; Cassorla, F.; Loriaux, Donald (Lynn); Merriam, G. R.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 59, No. 2, 1984, p. 197-201.

Research output: Contribution to journalArticle

@article{d594b7a5d9254b7095a721baecc09d86,
title = "Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women",
abstract = "Human GRF-(1-44)-NH2 (GRF-44) was administered iv in graded doses of 0.01-10 μg/kg to 35 normal young adult men and 38 women. GRF-44 stimulated the release of GH in a dose-dependent fashion, although the individual responses varied widely. The ED50 values for this effect were 0.4 μg/kg in men and 0.2 μg/kg in women in the midfollicular phase of the menstrual cycle. Maximal responses in men and women were not significantly different, and a dose of 1 μg/kg was sufficient to produce a maximal response. There was, likewise, no difference between responses of women tested in the midfollicular and midluteal phases of the cycle. There were no changes in PRL, LH, FSH, TSH, ACTH, β-endorphin, or cortisol at doses up to 1 μg/kg; at 10 μg/kg, PRL increased by an average of 7.6 ng/ml in the women. Side effects occurred in approximately 20{\%} of both men and women at 1 μg/kg and in nearly all subjects given 10 μg/kg; these consisted primarily of flushing and a sense of warmth. Thus, a dose of 1 μg/kg GRF-44 is safe and effective, and would appear to be a reasonable choice for use in studying GH responses in normal subjects of other ages and in patients with disorders of GH secretion.",
author = "Gelato, {M. C.} and Pescovitz, {O. H.} and F. Cassorla and Loriaux, {Donald (Lynn)} and Merriam, {G. R.}",
year = "1984",
language = "English (US)",
volume = "59",
pages = "197--201",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women

AU - Gelato, M. C.

AU - Pescovitz, O. H.

AU - Cassorla, F.

AU - Loriaux, Donald (Lynn)

AU - Merriam, G. R.

PY - 1984

Y1 - 1984

N2 - Human GRF-(1-44)-NH2 (GRF-44) was administered iv in graded doses of 0.01-10 μg/kg to 35 normal young adult men and 38 women. GRF-44 stimulated the release of GH in a dose-dependent fashion, although the individual responses varied widely. The ED50 values for this effect were 0.4 μg/kg in men and 0.2 μg/kg in women in the midfollicular phase of the menstrual cycle. Maximal responses in men and women were not significantly different, and a dose of 1 μg/kg was sufficient to produce a maximal response. There was, likewise, no difference between responses of women tested in the midfollicular and midluteal phases of the cycle. There were no changes in PRL, LH, FSH, TSH, ACTH, β-endorphin, or cortisol at doses up to 1 μg/kg; at 10 μg/kg, PRL increased by an average of 7.6 ng/ml in the women. Side effects occurred in approximately 20% of both men and women at 1 μg/kg and in nearly all subjects given 10 μg/kg; these consisted primarily of flushing and a sense of warmth. Thus, a dose of 1 μg/kg GRF-44 is safe and effective, and would appear to be a reasonable choice for use in studying GH responses in normal subjects of other ages and in patients with disorders of GH secretion.

AB - Human GRF-(1-44)-NH2 (GRF-44) was administered iv in graded doses of 0.01-10 μg/kg to 35 normal young adult men and 38 women. GRF-44 stimulated the release of GH in a dose-dependent fashion, although the individual responses varied widely. The ED50 values for this effect were 0.4 μg/kg in men and 0.2 μg/kg in women in the midfollicular phase of the menstrual cycle. Maximal responses in men and women were not significantly different, and a dose of 1 μg/kg was sufficient to produce a maximal response. There was, likewise, no difference between responses of women tested in the midfollicular and midluteal phases of the cycle. There were no changes in PRL, LH, FSH, TSH, ACTH, β-endorphin, or cortisol at doses up to 1 μg/kg; at 10 μg/kg, PRL increased by an average of 7.6 ng/ml in the women. Side effects occurred in approximately 20% of both men and women at 1 μg/kg and in nearly all subjects given 10 μg/kg; these consisted primarily of flushing and a sense of warmth. Thus, a dose of 1 μg/kg GRF-44 is safe and effective, and would appear to be a reasonable choice for use in studying GH responses in normal subjects of other ages and in patients with disorders of GH secretion.

UR - http://www.scopus.com/inward/record.url?scp=0021124948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021124948&partnerID=8YFLogxK

M3 - Article

C2 - 6330151

AN - SCOPUS:0021124948

VL - 59

SP - 197

EP - 201

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -